JPS6155486B2 - - Google Patents
Info
- Publication number
- JPS6155486B2 JPS6155486B2 JP53133754A JP13375478A JPS6155486B2 JP S6155486 B2 JPS6155486 B2 JP S6155486B2 JP 53133754 A JP53133754 A JP 53133754A JP 13375478 A JP13375478 A JP 13375478A JP S6155486 B2 JPS6155486 B2 JP S6155486B2
- Authority
- JP
- Japan
- Prior art keywords
- thiazolo
- pyrimidine
- inflammatory
- effects
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 10
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- CDUYCVWBLGEWSY-UHFFFAOYSA-N 5h-[1,3]thiazolo[3,2-a]pyrimidine Chemical class C1C=CN=C2SC=CN12 CDUYCVWBLGEWSY-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 239000000679 carrageenan Substances 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 229940113118 carrageenan Drugs 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000003230 pyrimidines Chemical class 0.000 description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 5
- 244000215068 Acacia senegal Species 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000002587 enol group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DNZPLHRZXUJATK-UHFFFAOYSA-N 2-sulfanylidene-5-[[5-[2-(trifluoromethyl)phenyl]furan-2-yl]methyl]-1,3-diazinane-4,6-dione Chemical compound FC(F)(F)C1=CC=CC=C1C(O1)=CC=C1CC1C(=O)NC(=S)NC1=O DNZPLHRZXUJATK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Landscapes
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13375478A JPS5562092A (en) | 1978-11-01 | 1978-11-01 | Antiphlogistic agent containing thiazolo 3,2-a pyrimidine derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13375478A JPS5562092A (en) | 1978-11-01 | 1978-11-01 | Antiphlogistic agent containing thiazolo 3,2-a pyrimidine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5562092A JPS5562092A (en) | 1980-05-10 |
| JPS6155486B2 true JPS6155486B2 (fr) | 1986-11-28 |
Family
ID=15112150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13375478A Granted JPS5562092A (en) | 1978-11-01 | 1978-11-01 | Antiphlogistic agent containing thiazolo 3,2-a pyrimidine derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5562092A (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0049902A3 (fr) * | 1980-10-15 | 1982-09-01 | Teijin Limited | Dérivés de la thiazolo(3,2-a)pyrimidine, procédé pour leur préparation et leur application pharmaceutique |
-
1978
- 1978-11-01 JP JP13375478A patent/JPS5562092A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5562092A (en) | 1980-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU781827B2 (en) | Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation | |
| JPS62215527A (ja) | アルツハイマー病治療薬 | |
| EP1014974B1 (fr) | Traitement de la schizophrenie et de la psychose | |
| KR100210199B1 (ko) | 자기면역질환요법을 위한 약제조성물 | |
| US20100016377A1 (en) | Use of a p38 Kinase Inhibitor for Treating Psychiatric Disorders | |
| CA2522971A1 (fr) | Methode pour ameliorer la diurese chez des personnes a fonction renale alteree | |
| US4292319A (en) | Antiphlogistic pharmaceutical compositions and method of use | |
| EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
| JPS6155486B2 (fr) | ||
| JP2872695B2 (ja) | 腎炎の治療剤 | |
| JP2965576B2 (ja) | 飲酒癖の処置のための薬剤 | |
| US6001865A (en) | 3-substituted 1-benzyl-1H-indazole derivatives as antifertility agents | |
| JPS5815912A (ja) | 消炎鎮痛剤 | |
| JPS6155485B2 (fr) | ||
| EP0132880B1 (fr) | Compositions pharmaceutiques à base d'épinine ou un sel pharmaceutiquement acceptable | |
| JP2548223B2 (ja) | 腎臓疾患治療剤 | |
| CZ20024153A3 (cs) | Léčivo pro prevenci a léčení neurogenerativních nemocí | |
| US4363809A (en) | Organic compounds | |
| DE3887426T2 (de) | Eperisone als Hypotonikum. | |
| EP0006845A1 (fr) | Composition pharmaceutique contenant un dérivé d'un acide 5-aroyle-1-alcoyle (C1-5) pyrrole-2-acétique et de l'acétaminophène ou de l'acide acétylsalicylique | |
| JPS6058726B2 (ja) | プリン誘導体を有効成分として含有する抗アレルギ−，鎮痛，鎮静剤 | |
| JPWO2004096230A1 (ja) | 関節リウマチ治療剤 | |
| JPS6092216A (ja) | 抗リウマチ剤 | |
| JPH0141126B2 (fr) | ||
| JPH1160482A (ja) | 性機能改善剤 |